New England Journal of Medicine· 2016Q1

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

Alexa B. Kimball, Martin M. Okun, David Williams, Alice B. Gottlieb et al.

783citations
Q1SCImago
2016year

Short summary

Adalimumab, administered weekly, significantly improved clinical response rates in patients with hidradenitis suppurativa (HS) compared to placebo in two Phase 3 trials (PIONEER I & II).

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Dermatology

DermatologyMedicine